Are there any special considerations for treatment of metastatic acral melanoma?

In general, acral melanoma is a higher-risk disease. There are higher rates of acquired and primary resistance. Given this, I favor ipi-nivo since the overall risk is higher and response rates to single-agent PD-1 or nivo-rela tend to be lower. Emerging data suggest TIL therapy can work reasonably w...

I tend to treat these patients aggressively and lean towards ipi/nivo in these patients. Will consider Nivo/Rela if poor performance status.